Chordia Therapeutics Inc. (JP:190A)
:190A
Want to see JP:190A full AI Analyst Report?
190A Stock Chart & Stats
¥108.00
-¥9.00(-2.81%)
At close: 4:00 PM EST
¥108.00
-¥9.00(-2.81%)
Day’s Range― - ―
52-Week Range¥98.00 - ¥241.00
Previous CloseN/A
Volume2.20M
Average Volume (3M)565.44K
Market Cap
¥7.72B
Enterprise Value¥5.75B
Total Cash (Recent Filing)¥2.55B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta0.67
Next Earnings
Jul 15, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-26.05
Shares Outstanding76,392,400
10 Day Avg. Volume542,310
30 Day Avg. Volume565,443
Financial Highlights & Ratios
PEG Ratio0.42
Price to Book (P/B)5.07
Price to Sales (P/S)0.00
P/FCF Ratio-6.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetHaving no reported debt materially lowers financial risk and preserves flexibility to fund R&D or pursue partnerships without immediate debt servicing. Over a 2–6 month horizon this reduces refinancing pressure and gives management optionality to shape development timelines or seek strategic collaborations.
Proven Revenue/profit HistoryDemonstrated ability to generate revenue and profits in 2023 shows the business and technology can translate into commercial outcomes. This historical proof point reduces binary development risk relative to never-revenue biotech peers and supports realistic pathways for licensing or staged commercialization over the medium term.
Focused Oncology Small-molecule R&DA concentrated oncology small-molecule focus targets a structurally growing therapeutic area with clear demand and multiple development/commercial pathways (partners, asset sales). Small team and targeted pipeline can improve capital efficiency and speed decision cycles versus broader, unfocused R&D models.
Bears Say
Zero Recent RevenueSustained absence of revenue eliminates margin support and forces operations to rely on financing. Over months this undermines internal funding of trials, raises dilution or partnership risk, and increases execution risk for advancing clinical programs without committed external funding.
Severe Cash BurnLarge, persistent negative operating and free cash flow shows the company is consuming cash rapidly. Without revenue or near-term milestone receipts, this creates an urgent need for financing or partnerships, increasing dilution risk and potentially forcing program slowdowns that impair long-term value creation.
Eroding Equity And ReturnsMaterial decline in equity and deeply negative ROE indicate the capital base is being consumed by losses. This weakens the company’s balance-sheet buffer, limits its ability to absorb further setbacks, and increases dependence on external capital or dilutive financing over the coming months.
Chordia Therapeutics Inc. News
190A FAQ
What was Chordia Therapeutics Inc.’s price range in the past 12 months?
Chordia Therapeutics Inc. lowest stock price was ¥98.00 and its highest was ¥241.00 in the past 12 months.
What is Chordia Therapeutics Inc.’s market cap?
Chordia Therapeutics Inc.’s market cap is ¥7.72B.
When is Chordia Therapeutics Inc.’s upcoming earnings report date?
Chordia Therapeutics Inc.’s upcoming earnings report date is Jul 15, 2026 which is in 35 days.
How were Chordia Therapeutics Inc.’s earnings last quarter?
Chordia Therapeutics Inc. released its earnings results on Apr 10, 2026. The company reported -¥4.71 earnings per share for the quarter, missing the consensus estimate of N/A by -¥4.71.
Is Chordia Therapeutics Inc. overvalued?
According to Wall Street analysts Chordia Therapeutics Inc.’s price is currently Overvalued.
Does Chordia Therapeutics Inc. pay dividends?
Chordia Therapeutics Inc. does not currently pay dividends.
What is Chordia Therapeutics Inc.’s EPS estimate?
Chordia Therapeutics Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Chordia Therapeutics Inc. have?
Chordia Therapeutics Inc. has 76,392,400 shares outstanding.
What happened to Chordia Therapeutics Inc.’s price movement after its last earnings report?
Chordia Therapeutics Inc. reported an EPS of -¥4.71 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.775%.
Which hedge fund is a major shareholder of Chordia Therapeutics Inc.?
Currently, no hedge funds are holding shares in JP:190A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Chordia Therapeutics Inc.
Chordia Therapeutics specializes in oncology, with its efforts spanning the entire drug discovery and development pipeline, from initial exploratory research through to Proof of Concept (POC) validation. To optimize future business growth and enhance corporate value, we are establishing a robust strategic framework that will guide decisions on approaches such as out-licensing, co-development partnerships, and joint commercialization efforts.
Technical Analysis
Pharmarise Holdings Corp.
―
COSMOS Pharmaceutical Corporation
―
Tsubota Laboratory Incorporated
―
Shinnihonseiyaku Co., Ltd.
―
Heartseed, Inc.
―